Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension

M. A. Munger, W. F. Rutherford, L. Anderson, A. I. Hakki, F. M. Gonzalez, E. M. Bednarczyk, G. Emmanuel, S. G. Weed, Edward A Panacek, J. A. Green

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 μg/kg·min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (≥ 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p < .001) with no sigificant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.

Original languageEnglish (US)
Pages (from-to)502-504
Number of pages3
JournalCritical Care Medicine
Volume18
Issue number5
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension'. Together they form a unique fingerprint.

  • Cite this

    Munger, M. A., Rutherford, W. F., Anderson, L., Hakki, A. I., Gonzalez, F. M., Bednarczyk, E. M., Emmanuel, G., Weed, S. G., Panacek, E. A., & Green, J. A. (1990). Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Critical Care Medicine, 18(5), 502-504.